OTC Claritin Sales Reach $105 Mil. In Fourth Quarter
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough's sales of OTC Claritin (loratadine) totaled $105 mil. in the final quarter of 2002, the company announced in a Jan. 23 conference call
You may also be interested in...
Novartis Tavist ND Loratadine Tablets Carry Geneva’s Marketing Exclusivity
Geneva Pharmaceuticals initially will market the first generic competition to Schering-Plough's OTC Claritin behind pharmacy counters
Wyeth Alavert Approval Sparks Loratadine Price Wars, Fight For OTC Share
Wyeth Consumer Healthcare is staking a claim to the OTC loratadine market with Alavert pricing of 56¢ to $1 per orally disintegrating tablet and high-value coupons
Schering OTC Claritin Post-Approval Filings To Include Hypospadia Reports
Schering-Plough's post-approval commitments for OTC Claritin include submitting to FDA reported cases of the birth defect hypospadia following maternal ingestion of loratadine, the company said